IGFBP3 and cholangiocarcinoma: On the other hand, higher IGFBP-3 was suggestive of better survival outcome in lymphoid neoplasm diffuse large B-cell lymphoma (FDR = 2.58∙10−2 (HR = 0.14)), breast cancer (1.20∙10−1 (HR = 0.74)), prostate adenocarcinoma (3.43∙10−1 (HR = 0.51)), cholangiocarcinoma (4.84∙10−1 (HR = 0.57)), bladder urothelial carcinoma (3.63∙10−1 (HR = 0.84)), and uterine carcinosarcoma (6.65∙10−1 (HR = 0.860)) (Figure 6D–F).